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ABSTRACT 
Background: We evaluated cancer incidence in a cohort of polychlorinated biphenyl (PCB) 
exposed workers. 
Methods: Incident cancers, identified using state registries, were compared to those in a national 
population using standardized incidence ratios. Trends in prostate cancer incidence with 
cumulative PCB exposure were evaluated using standardized rate ratios and Cox regression 
models. For selected sites, cumulative PCB exposure compared between aggressive (fatal/distant 
stage) and localized/regional cancers. 
Results: We identified 3371 invasive first primary cancer diagnoses among 21,317 eligible 
workers through 2007. Overall relative incidence was reduced. Elevations were only observed 
for respiratory cancers and among women, urinary organ cancers. Among men, prostate cancer 
incidence was reduced and not associated with cumulative PCB exposure although median 
exposures were significantly higher for aggressive compared to localized/regional prostate 
cancers. 
Conclusion: Previously observed associations between cumulative PCB exposure and prostate 
cancer mortality were not confirmed in this analysis; prostate cancer stage at diagnosis may 
explain the discrepancy. 
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INTRODUCTION 
Cohort mortality studies have long been a mainstay of occupational cancer epidemiology. 
However, for cancer sites with high survivability, mortality studies may not be the best way to 
investigate the relation between exposure to a carcinogen and the risk of cancer [Boyle 1989]. 
 
The National Institute for Occupational Safety and Health (NIOSH) polychlorinated biphenyl 
(PCB) cohort includes 24,865 capacitor-manufacturing workers exposed to PCBs from 1938-
1977 at plants in Indiana, Massachusetts, and New York. For several a priori sites, including 
prostate cancer, a mortality update showed significant exposure-response relations between 
exposure and mortality [Ruder, et al. 2014]. Among long-term workers (≥90 days of 
employment), prostate cancer mortality (78 deaths) was significantly associated with cumulative 
PCB exposure and was significantly elevated (25 deaths, standardized rate ratio (SRR) 2.11, 95% 
confidence interval (CI) 1.08–4.13) in the highest (≥600,000 unit-days) relative to the lowest 
(<40,000 unit-days) exposure category [Ruder, et al. 2014]. 
 
To determine if prostate cancer incidence in the National Institute for Occupational Safety and 
Health (NIOSH) PCB cohort would parallel our cancer mortality findings, we conducted a 
cancer incidence study on this cohort using data from cancer registries in the three study states 
and six additional states to which substantial numbers of cohort members had moved. We 
focused on prostate cancer, based on our mortality study results and its high survivability 
(~100% five-year survival and 99% ten-year survival) [American Cancer Society 2013], but we 
evaluated all sites for both sexes. 
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METHODS 
Details about cohort enumeration and mortality are presented in detail elsewhere [Ruder, et al. 
2014] and briefly here. The cohort includes everyone with complete demographic information 
employed at the study facilities for one day or more while PCBs were in use (n=24,865). To 
ascertain vital status, worker data were linked to the Social Security Administration and the 
National Death Index (NDI). Causes of death were obtained from NDI Plus for deaths in 1979 or 
later; for earlier deaths, death certificates were obtained from state vital statistics offices and 
coded to the International Classification of Diseases revision in effect at the time of death. 
 
All workers were matched to cancer registries in New York, Massachusetts, and Indiana, with 
complete ascertainment beginning in 1976, 1982, and 1987, respectively. To minimize losses due 
to migration, we also matched workers to cancer registries in Connecticut, Rhode Island, 
California, Texas, Florida, and North Carolina, with complete ascertainment beginning in 1973, 
1986, 1988, 1995, 1997, and 1999, respectively. Registries provided matching through 
December 31, 2007. After excluding workers who had died (n=1306) or were lost to follow-up 
(n=656) before their respective cancer registries were operating, 22,903 workers were initially 
eligible for the primary cancer incidence analysis (10,693 male workers for the prostate cancer 
analysis). Through 2007, 7006 (31%) of the eligible workers had died with 6055 (86%) of these 
deaths occurring in the registry states (Supplemental File, Table S1). 
 
Cancer registries provided date of diagnosis and International Classification of Diseases for 
Oncology Third Edition (ICD-O-3) codes for primary site, laterality, morphology, and stage. 
Incident cases (all primary invasive cancers and in situ bladder cancers) were classified into 12 
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major and 41 minor cancer incidence groupings (Supplemental File, Table S2). Diagnosis dates 
were assigned as January 1st if only the year was known, and on the 1st of the month if only the 
month and year were known. For prostate cancer, the rate of case under-ascertainment by using 
death certificates to identify cases was estimated using methods in Freedman et al. [Freedman, et 
al. 2006]. For analysis of first primary invasive cancer, we excluded workers diagnosed before 
their respective cancer registries were operating. For analysis of prostate cancer, we excluded 
men with prostate cancer diagnoses before their respective cancer registries were operating, but 
not men with other cancer diagnoses. 
 
Historical address information was used to estimate when workers first entered and first left the 
time-dependent catchment area (hereafter “the catchment”). The catchment first encompassed 
Connecticut from 1973-1975. New York joined the catchment in 1976; over time the catchment 
was enlarged until for 1999-2007 it included all nine states. Available address information was 
combined to form a residence history for each worker (see Supplemental File, Additional 
details on state of residence). For a given year, workers were considered to be in the catchment 
if living in any state associated with the catchment. Workers thought to never 
have lived in the catchment were excluded. Workers leaving the catchment before the study end 
date contributed person-years at risk (PYAR) until they left. Although some workers may have 
returned to the catchment, the primary analysis (described below) only considered the initial risk 
period. 
 
Detailed work history records included begin date, end date, department, and job title. Plant-
specific job exposure matrices were used to assign exposure scores for inhalation and dermal 
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exposure to PCBs [Hopf, et al. 2014; Hopf, et al. 2009; Hopf, et al. 2010]. An un-weighted 
average of inhalation and dermal exposure scores was used to estimate cumulative exposure (the 
product of the number of days in each department and job-title and the assigned score, summed 
over all jobs worked), which was expressed as unit-days or unit-years. 
 
Cohort cancer rates were compared to rates in the Surveillance, Epidemiology, and End Results 
(SEER) referent population, which covers approximately 28% of the US population [Howlader, 
et al. 2014] using standardized incidence ratios (SIRs) from a life-table analysis program 
(LTAS.NET) [Schubauer-Berigan, et al. 2011]. In this analysis, the numerator was based on first 
primary invasive cancers among eligible cohort members. Analyses of the first primary invasive 
cancer (overall and site-specific) used SEER 1976-2009 rates adjusted for cancer prevalence 
[Merrill, et al. 2012]. SIRs were also used to compare prostate cancer rates among male workers 
to the SEER referent population; in this analysis, the first primary prostate cancer was considered 
(and other earlier cancers were ignored) and reference rates were based on SEER data (1976-
2006) unadjusted for cancer prevalence (i.e., all prostate cancers were considered). 
 
For each worker, the date risk began was the later of the date of first employment and the date 
the worker entered the catchment. The date risk ended was the earliest of the date of diagnosis 
(cases), the date last observed (workers lost to follow-up), the date of death (deceased workers), 
the date the worker left the catchment (if applicable), and the study end date (workers alive, 
cancer free, and still in the catchment on 12/31/2007). Person-time at risk was stratified by age 
and calendar year (in 5-year categories) and multiplied by gender- and race-specific cancer 
incidence rates to obtain expected numbers of cases. The SIR was defined as the ratio of the 
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observed to the expected numbers of cases and 95% CIs were estimated under the assumption of 
a Poisson distribution. Race was unknown for over half of the cohort [Ruder, et al. 2014]; White 
race was assumed when unknown based on plant locations. 
 
The primary analysis used cancer registry data to identify cases and registry states to define the 
catchment. Sensitivity analyses for prostate cancer explored different scenarios: limiting the 
catchment to the three plant states and limiting cases to those identified using these registries; 
additionally including cases identified using death certificates from the nine registry states; 
including all risk periods (i.e., all person-time at risk in the catchment contributed to the 
denominator); assigning the earlier state to the entire gap in the residence history; assigning the 
later state to the entire gap; and excluding nine “lost and found” workers. Additional details of 
these sensitivity analyses are provided (Supplemental File, Sensitivity Analyses). 
 
Prostate cancer incidence was compared by plant state (Indiana, Massachusetts, and New York) 
and by employment duration (<90 days, 90+ days) (Supplemental File, External analyses) for 
details). Standardized rate ratios and Cox proportional hazards regression models were used to 
evaluate associations between prostate cancer incidence and cumulative PCB exposure 
(Supplemental File, Internal analyses). 
 
Finally, we conducted a post hoc analysis comparing cumulative PCB exposure for aggressive 
prostate cancer diagnoses to indolent prostate cancer diagnoses, using the definition of Koutros 
et al that aggressive prostate cancers were fatal (underlying cause prostate cancer) or distant 
stage at diagnosis [Koutros, et al. 2013]. Lacking another metric, we applied this definition 
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across cancer sites, and defined an aggressive cancer as fatal (with the underlying cause of death 
being the same cancer) or distant stage at diagnosis. Because the distribution of cumulative PCB 
exposure was highly right-skewed, we compared median exposures for aggressive cases to 
indolent cases (localized or regional stage at diagnosis) using the Wilcoxon two-sample test. 
 
This study (HSRB-08-DSHEFS-02) was approved by the NIOSH Human Subjects Review 
Board and participating state cancer registries. As a records study, it was exempted from 
informed consent requirements. 
 
RESULTS 
Among eligible workers 4084 invasive cancer diagnoses occurred; all after the workers began 
employment. With only a few exceptions (n=8), all diagnoses occurred after the workers ended 
employment. We excluded 121 duplicate matches and 304 later diagnoses among workers with 
multiple primary diagnoses (for 21 workers with multiple primary tumors on the same day, we 
selected the most common cancer); 33 workers diagnosed before their respective cancer registry 
began operation; 1507 workers (53 diagnoses) with no time in the catchment; and 46 workers 
diagnosed before entering the catchment. We censored PYAR for 2244 workers who left the 
catchment before the study end date (and ignored 156 subsequent diagnoses in this group). 
 
Cancer case and non-case demographics are in Table 1. For the analysis of first primary invasive 
cancer, 3371 cases were observed among 21,317 workers contributing 427,511.2 PYAR. Cancer 
incidence was significantly reduced (SIR 0.93, 95% CI 0.90-0.96) (Table 2). Significant 
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elevations were observed for respiratory cancers overall (SIR 1.23, 95% CI 1.14-1.33) and 
urinary organ cancers among females (SIR 1.27, 95% CI 1.01-1.53). 
 
For the prostate cancer analysis, we considered all prostate cancer matches (n=501) regardless of 
other diagnoses. We excluded three duplicate matches and one second primary match; three 
workers with prostate cancer diagnoses before their respective cancer registry began operation; 
776 workers (five diagnoses) with no time in the catchment; and nine workers with prostate 
cancer diagnoses before entering the catchment. We censored PYAR for 1,345 workers who left 
the catchment before the study end date (and ignored 26 subsequent diagnoses). This analysis 
included 454 prostate cancer cases, whether first primary or not, among 9,905 workers 
contributing 193,960.3 PYAR. Prostate cancer incidence was lower than expected (SIR 0.88, 
95% CI 0.80-0.97). Prostate cancer incidence did not vary by plant; was similar for short-term 
(<90 days of employment) and long-term workers; and did not vary with unlagged or 20-year 
lagged cumulative exposure (Supplemental File, Table S3). Sensitivity analyses for defining 
the catchment, cases, and risk periods produced similar results (Supplemental File, Table S4). 
 
As of 12/31/2007, 338 prostate cancer cases were alive, five were lost to follow-up, 142 had died 
in the catchment, and 12 had died outside of the catchment. For the 142 deaths in the catchment, 
the death certificate specified prostate cancer as the underlying cause for 53 decedents and as a 
contributing cause for an additional 10 decedents. Consequently, death certificate ascertainment 
did not identify 56% (79 out of 142) of the prostate cancers identified by the state cancer 
registries among cohort members who had died in one of the registry states by 12/31/2007. 
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In internal analyses, directly standardized rates of prostate cancer incidence did not increase with 
unlagged or 20-year lagged categories of cumulative exposure (Supplemental File, Table S5). 
Similar results were observed when exposure lag periods of 10 and 30 years were considered and 
when short-term (<90 days employment) workers were excluded (data not shown). Risk of 
prostate cancer was not associated with cumulative PCB exposure in Cox regression models 
(Supplemental File, Table S6). 
 
The incident cancer diagnoses are described in Table 3 by their status as aggressive or indolent. 
Median estimated cumulative PCB exposure is summarized for aggressive and indolent cancer 
diagnoses in Table 4 for 11 major categories and some minor categories of special interest 
(stomach, uterine, and brain cancer because of previously observed elevated mortality [Ruder et 
al 2014]). Among prostate cancer cases with known exposure and known status, the median 
cumulative exposures for aggressive cancer cases was significantly higher compared to localized 
and regional cases. The median was higher, but not significantly, for respiratory cancers. 
 
DISCUSSION 
Cancer is a major public health problem in the United States with annual incidence of 
460.4/100,000 (1.67 million diagnoses estimated for 2014) and annual mortality of 
174.8/100,000 (585,720 deaths estimated for 2014) [Howlader, et al. 2014]. In the United States, 
prostate cancer accounts for more male cancer diagnoses than lung cancer and, despite the high 
survival rate, is a leading cause of death [Brawley 2012]. The known risk factors for prostate 
cancer are advanced age, family history, African-American race [Brawley 2012], and higher 
latitude of residence [St-Hilaire, et al. 2010]. While there are no well-established occupational or 
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environmental risk factors, exposures to PCBs [Charles, et al. 2003; Ruder, et al. 2014] and 
pesticides [Ejaz, et al. 2004; Mullins and Loeb 2012] have been proposed. For several sites, 
including prostate cancer, our mortality update showed significant exposure-response 
relationships [Ruder, et al. 2014]. For cancers with high survivability, incidence may be a better 
metric than mortality. Indeed, in our study, death certificates missed more than half of the 
prostate cancer diagnoses. Consequently, we analyzed incident cancers, to determine whether 
cancer groupings for which we had found excess mortality would also have elevated cancer 
incidence. 
 
We expected to find elevated prostate cancer incidence in this cohort of PCB exposed workers 
because of the previously observed positive exposure-response relation with cumulative PCB 
exposure and prostate cancer mortality; however, prostate cancer incidence was significantly 
reduced in the cohort compared to the SEER population. Furthermore, elevations were not 
observed for other incident cancers with the exception of respiratory cancers and, among women, 
urinary organ cancers. We considered several possible explanations for this apparent 
discrepancy. 
 
First, our study could not benefit from a national cancer registry, as one does not exist 
[Buchanich, et al. 2009]. We identified cases using cancer registries for nine states where 86% of 
deceased eligible workers had died through 2007. Cancer diagnoses outside of the catchment 
area or before the registries were operating were not available. Consequently, person-time for 
individuals outside the catchment was excluded when estimating expected numbers of cases. 
This calculation, however, relied on available residential histories, and the state of residence had 
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to be assumed for 43% of the potential PYAR. Overestimation of the amount of time spent in the 
catchment would result in underestimated SIRs. 
 
Second, our analyses used SEER rates, which are intended to be representative of the entire 
country. However, the SEER catchment comprises only 28% of the U.S. population [National 
Cancer Institute 2015]. If SEER rates actually overestimate national incidence, then SIRs would 
be underestimated. Ideally, a comparison of mean prostate cancer incidence rates inside and 
outside the SEER catchment could test this hypothesis for prostate cancer but rates for individual 
states outside the SEER catchment are unfortunately only available for more recent years and not 
for all of the years considered in our study. However, an examination of state-specific prostate 
cancer incidence rates for recent years [Centers for Disease Control and Prevention and National 
Cancer Institute 2014] showed that Indiana incidence (but not Massachusetts or New York) was 
consistently below SEER incidence, so use of the SEER rates may have underestimated the 
prostate cancer SIR. 
 
Third, our cohort is an older cohort and it is possible that members of our cohort were diagnosed, 
and subsequently died, before registries began collecting cases. Median birth year was 1930 
(range 1896-1957) for women diagnosed with cancer and 1932 (range 1900-1958) for men 
diagnosed with cancer; median birth year was 1938 (range 1890-1959) for cancer-free women 
and 1942 (range 1888-1960) for cancer-free men (Table 1). Since most cancer registries began 
ascertaining cases in 1976-1999, information about nonfatal cancer diagnoses among the 1306 
workers who died before 1976 or the 656 workers lost to follow-up (8% of the cohort) would not 
have been ascertained by us and these individuals would not have been included in our analysis. 
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Fourth, race was unknown, and White race assumed, for over half the cohort [Ruder, et al. 2014]. 
Thus, it is possible that rates applied were too high or too low for a subset of the cohort. For 
example, because prostate cancer incidence rates are higher for African-American men [Brawley 
2012], if African-American rates were more appropriate for some of the men with unknown race, 
use of the higher rates would have resulted in increased expected incidence, but this would have 
resulted in an even lower prostate cancer SIR. 
 
Fifth, for the external analyses, we used two prostate cancer incidence rate files for the SEER 
referent population [Howlader, et al. 2014]. The first rate file (a) excluded second and later 
diagnosed cases from the numerator and (b) excluded prevalent cases from the denominator and 
produced an SIR of 0.83 (Table 2); the second rate file, which was only used for prostate cancer, 
(a) did not exclude second and later diagnosed cases from the numerator (although this is not 
likely to be a major issue for prostate cancer) and (b) did not exclude prevalent cases from the 
denominator (a potentially major issue given the high prevalence of prostate cancer in the United 
States) and produced an SIR of 0.88 (Supplemental File, Tables S3-S5). Merrill and colleagues 
estimated corrected prostate cancer incidence rates to be 9.9-13.7% higher than rates that did not 
include these adjustments [Merrill, et al. 2012]. Larger differences were observed at older ages, 
with corrected rates for white males 80 years or older estimated to be 20% higher than 
uncorrected rates [Merrill and Sloan 2012]. Thus, in the second analysis it is possible that we 
underestimated the expected number of prostate cancer cases and consequently overestimated the 
prostate cancer SIRs, but this does not explain the observed deficit or the lack of association with 
estimated exposure to PCBs.  
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Finally, recommendations for screening using prostate-specific antigen (PSA) testing in the late 
1980s had an enormous impact on the numbers of diagnoses in subsequent years [Leach and 
Thompson 2012], but adherence to screening guidelines can vary. For example, screening for 
working Americans with no cancer history (based on National Health Interview Survey data) 
varied by job status with 53% and 61% of blue- and white-collar men screened in 1999, 
respectively, and declining to 37% and 50% by 2010 [Clarke, et al. 2012]. If the men in our 
cohort were less likely than other men to be screened, prostate cancer diagnoses would have been 
under ascertained in our cohort, leading to underestimated prostate cancer SIRs.  
 
We did not observe positive associations between prostate cancer incidence and estimated 
cumulative PCB exposure in this cohort of PCB exposed workers. Both duration of employment 
and estimated PCB exposure in our cohort decreased with decade of first exposure (data not 
shown) so differential PSA screening rates by year could obscure an exposure-response 
association. In a post hoc analysis, we observed significantly higher median estimated 
cumulative PCB exposure for workers with aggressive prostate cancer diagnoses (median 700 
unit-years) compared to regional/localized diagnoses (median 150 unit-years) (Table 4; 
p<0.0001). Since prostate cancer aggressiveness may be determined when the tumor is initially 
formed (Giovannucci et al 2006; Penney et al 2013), it is possible that higher exposed workers 
developed aggressive tumors differentially at a higher rate compared to lower exposed workers. 
However, given the number of prostate risk factors and the role genetic susceptibility plays, it is 
difficult to interpret the difference in PCB exposure we observed (Boyd et al 2012). 
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There are limited and conflicting data on the relationship between PCBs and prostate cancer. In a 
serum concentration study Koutros et al (2015) found no association between total PCBs and 
individual PCB congeners and metastatic prostate cancer except for PCB congener 44 which was 
inversely associated with risk. Sawada et al. (2010) found an inverse risk of total PCBs in plasma 
and advanced prostate cancer. Since the workers in our cohort were exposed to PCB mixtures 
which contained estrogenic, nonestrogenic, and antiandrogenic PCB congeners (Connor et al 
1997, Wolff et al 1997, Hopf et al 2009), etiologic mechanisms are likely complicated. 
 
Based on the known association of PCBs with endocrine disruption [Annamalai and 
Namasivayam 2015; Bonefeld-Jorgensen, et al. 2014], we expected to observe similar aggressive 
versus indolent results for other cancers associated with hormone effects (i.e., breast, uterine, 
ovarian, and thyroid cancers) [Buranatrevedh and Roy 2001; Duntas 2015]. However, we did not 
observe higher median cumulative PCB exposures for aggressive breast, uterine, and ovarian 
cancers. For thyroid cancer, the median cumulative PCB exposure for aggressive cancers was an 
order of magnitude higher compared to local/regional cancers but there were only two aggressive 
thyroid cancers.  While suggestive of an association, this should be explored in a larger study.  
 
Our mortality paper [Ruder, et al. 2014] did not focus on lung cancer because it was not an a 
priori outcome and we did not have smoking data on cohort members.  Smoking is the most 
important risk factor for lung cancer [Recio-Vega, et al. 2013] .  While lung cancer mortality was 
(borderline) elevated in the full cohort (766 deaths, SMR 1.07, 95% CI, 0.99-1.15), the elevation 
disappeared when we removed the short-term (< 90 days) workers (short-term SMR 1.34, long-
term SMR 0.99).  Several papers have associated serum PCB levels with elevated lung cancer 
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rates in non-occupational studies, whether not adjusting [Li, et al. 2015; Onozuka, et al. 2009] or 
adjusting [Recio-Vega, et al. 2013] for smoking status.  The present cancer incidence study also 
found elevated respiratory cancer in a PCB cohort but additional studies with both occupational 
exposure and smoking data would be needed to confirm the association. 
 
Our study has several significant strengths. It is the largest cohort of former capacitor workers 
exposed to PCBs and includes a detailed exposure assessment. The data available to construct 
job-exposure matrices included individual work histories, detailed job descriptions, and exposure 
measurements collected at the plants [Hopf, et al. 2014; Hopf, et al. 2009; Hopf, et al. 2010]. 
However, as in other records-based studies, we had no information on family history or genetic 
susceptibility; lifestyle choices that could affect mortality (such as obesity); or previous or 
subsequent employment. 
 
In conclusion, previously observed associations with cumulative PCB exposure and prostate 
cancer mortality were not confirmed in this analysis; however, prostate cancer stage may explain 
the apparent discrepancy. Our results may contribute to the decision-making process for 
determining which men could benefit from PSA testing. Men with aggressive prostate cancer had 
significantly higher levels of estimated cumulative PCB exposure than those with nonaggressive 
cancer. If it follows that incidence of aggressive prostate cancer is higher among men with high 
cumulative PCB exposure, then men who have been exposed to high levels of PCBs might 
benefit from PSA testing even more than men in the general population. 
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Cancer incidence data used in this study were also obtained from cancer registries in Indiana, 
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Table 1: Characteristics of analyzed workers, by case status, as of 31 December 2007 
 
Characteristic 
Female workers (n=11,426) 
 
Male workers (n=9,891) 
Cancer cases 
(n=1,822) 
No. (%) 1 
Other female workers 
(n=9,604) 
No. (%) 1 
Cancer cases 
(n=1,549) 
No. (%) 1 
Other male workers 
(n=8,342) 
No. (%) 1 
Plant      
Indiana 1138 (62) 6081 (63)  588 (38) 2728 (33) 
Massachusetts 580 (32) 2829 (30)  633 (41) 3737 (45) 
New York 104 (6) 595 (6)  328 (21) 1877 (23) 
Vital status as of 31 December 
2007      
Alive 724 (40) 7297 (76)  638 (41) 6141 (74) 
Dead 1087 (60) 2278 (24)  904 (58) 2165 (26) 
Lost 11 (<1) 29 (<1)  7 (<1) 36 (<1) 
Year of birth      
Median (range) 1930 (1896-1957) 1938 (1890-1959)  1932 (1900-1958) 1942 (1888-1960) 
Year of first employment      
Median (range) 1957 (1939-1977) 1962 (1939-1977)  1959 (1939-1977) 1965 (1939-1977) 
Age at first employment      
Median (range) 24.9 (15.2-58.3) 21.3 (14.-64.9)  24.5 (11.5-60.7) 22.1 (14.5-66.7) 
Age at last employment      
Median (range) 30.7 (16.0-68.2) 25.2 (15.9-69.7)  29.5 (16.1-66.1) 24.6 (15.3-72.0) 
Duration of employment (years)      
<90 days 543 (30) 3190 (33)  364 (23) 2273 (27) 
90 days -< 1 year 347 (19) 2179 (23)  345 (22) 2262 (27) 
1 year -< 5 years 433 (24) 2318 (24)  362 (23) 1950 (23) 
5 years -< 10 years 182 (10) 794 (8)  117 (8) 801 (10) 
10+ years 317 (17) 1123 (12)  361 (23) 1056 (13) 
Mean ± standard deviation 4.7 ± 7.3 3.5 ± 6.1  5.7 ± 8.1 3.7 ± 6.1 
Median (range) 1.0 (0.0-35.1) 0.7 (0.0-35.0)  1.3 (0.0-35.9) 0.8 (0.0-37.0) 
Cumulative exposure to PCBs 
(unit-years) 2      
Unknown 3 77 (4) 250 (3)  27 (2) 76 (1) 
Mean ± standard deviation 850 ± 2100 630 ± 1700  1000 ± 2300 640 ± 1600 
Median (range) 100 (0.1-22000) 73 (0.0-26000)  160 (0.3-21000) 110 (0.0-23000) 
 
1 Result given as n (%), unless otherwise specified. Percentages may not sum to 100 due to 
rounding. 
2 PCBs: polychlorinated biphenyls 
3 Cumulative exposure was unknown if workers had any time in a job with unknown exposure. 
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Table 2: First primary cancer standardized incidence ratios, by gender and overall 1 
First primary cancer 2 
Males 
(n=9,891) 
 
Females 
(n=11,426) 
 
Overall 
(n=21,317) 
OBS SIR 95% CI OBS SIR 95% CI OBS SIR 95% CI 
All cancers combined 1549 0.92 0.87-0.96  1822 0.94 0.90-0.98  3371 0.93 0.90-0.96 
MN of buccal and pharynx 39 0.70 0.50-0.96  25 0.80 0.52-1.19  64 0.74 0.57-0.94 
MN of colon and rectum 157 0.88 0.74-1.02  225 1.08 0.94-1.23  382 0.98 0.89-1.09 
MN of other digestive organs and peritoneum 135 1.00 0.84-1.19  111 0.89 0.73-1.07  246 0.95 0.83-1.08 
MN of stomach 40 1.23 0.88-1.68  18 0.79 0.47-1.25  58 1.05 0.80-1.36 
MN of respiratory and intrathoracic organs 344 1.16 1.04-1.29  354 1.31 1.18-1.45  698 1.23 1.14-1.33 
MN of breast 6 1.81 0.66-3.93  500 0.80 0.73-0.87  506 0.80 0.73-0.88 
MN of female genital organs 0    235 0.90 0.79-1.02  235 0.90 0.79-1.02 
MN of the uterus 0    105 0.77 0.63-0.93  105 0.77 0.63-0.93 
MN of the ovary 0    70 0.93 0.72-1.17  70 0.93 0.72-1.17 
MN of male genital organs 436 0.82 0.75-0.90  0    436 0.82 0.75-0.90 
MN of prostate 432 0.83 0.76-0.92  0    432 0.83 0.76-0.92 
MN of urinary organs 153 0.94 0.80-1.11  106 1.27 1.01-1.53  259 1.05 0.93-1.19 
MN of thyroid and other endocrine organs 7 0.56 0.22-1.15  14 0.43 0.23-0.72  21 0.46 0.29-0.71 
MN of other solid cancers 96 0.76 0.62-0.93  68 0.70 0.54-0.88  164 0.73 0.62-0.85 
MN of the brain 20 0.82 0.50-1.26  19 0.80 0.48-1.25  39 0.81 0.58-1.11 
MN of lymphatic and hematopoietic organs 131 0.88 0.73-1.04  139 0.93 0.78-1.09  270 0.90 0.80-1.01 
Ill-specified and residual 45 1.11 0.81-1.49  45 0.89 0.65-1.19  90 0.99 0.80-1.22 
 
MN – malignant neoplasm, OBS – observed number of cases, SIR – standardized incidence 
ratio, CI – confidence interval 
 
1 The analysis included cases of first primary incident cancers identified using the nine state 
cancer registries (Connecticut, New York, Massachusetts, Rhode Island, Indiana, California, 
Texas, Florida, and North Carolina); split any gaps in the residence history at the midpoint 
and assigned the first half of the gap to the earlier state and the second half of the gap to the 
later state; and limited person-time at risk to the initial risk period (i.e., person-time at risk 
was censored at the date the worker was first known to be living outside the catchment). 
2 Results for all major cancer sites and selected minor cancer sites. Specific ICD-O-3 codes 
associated with each grouping are listed in Supplemental File, Table S2. 
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Table 3: Cancer diagnoses by type 
 
First primary cancer Aggressive 1 In Situ Localized Regional Unknown Total 
All cancers combined 1509 59 1040 371 392 3371 
MN of buccal and pharynx 21 0 15 27 1 64 
MN of colon and rectum 145 0 90 108 39 382 
MN of other digestive organs and peritoneum 186 0 27 17 16 246 
MN of the stomach 36 0 10 7 5 58 
MN of respiratory and intrathoracic organs 526 0 87 46 39 698 
MN of breast 125 0 241 70 70 506 
MN of female genital organs 101 1 83 17 33 235 
MN of the uterus 27 1 48 6 23 105 
MN of the ovaries       
MN of male genital organs 52 0 303 36 45 436 
MN of the prostate 51 0 301 36 44 432 
MN of urinary organs 60 58 101 16 24 259 
Female 30 19 40 7 10 106 
Male 30 39 61 9 14 153 
MN of thyroid and other endocrine organs 2 0 13 2 4 21 
MN of other solid cancers 66 0 56 13 29 164 
MN of the brain 26 0 5 1 7 39 
MN of lymphatic and hematopoietic organs 220 0 20 17 13 270 
Multiple myeloma 40 0 0 0 0 40 
Ill-specified and residual 5 0 4 2 79 90 
MN – malignant neoplasm 
1 Aggressive is defined as distant stage at diagnosis or underlying cause of death due to same 
cause as cancer diagnosis. 
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Table 4: Estimated median cumulative PCB exposure levels (unit-years) for aggressive 
versus non-aggressive (localized or regional) diagnoses 1 
 
First primary cancer 
Localized/Regional 
 
Aggressive 2 
P-value 3 No. Median No. Median 
MN of buccal and pharynx 40 120  20 100 0.94 
MN of colon and rectum 191 150  140 140 0.86 
MN of other digestive organs and peritoneum 43 390  179 160 0.080 
MN of the stomach 17 410  33 510 0.98 
MN of respiratory and intrathoracic organs 133 70  517 120 0.074 
MN of breast 302 96  119 87 0.96 
MN of female genital organs 97 61  94 100 0.48 
MN of the uterus 52 73  25 110 0.25 
MN of the ovary 15 120  48 120 0.77 
MN of male genital organs 336 150  51 700 <0.0001 
MN of prostate 334 150  50 630 <0.0001 
MN of urinary organs 115 170  59 310 0.89 
Female 46 70  30 190 0.28 
Male 69 350  29 320 0.74 
MN of thyroid and other endocrine organs 15 160  2 3000 0.11 
MN of other solid cancers 67 59  64 78 0.44 
MN of the brain 6 31  25 110 0.15 
MN of lymphatic and hematopoietic organs 37 110  211 120 0.68 
 
MN – malignant neoplasm 
 
1 Limited to diagnoses for workers with no time in an unknown job category. 
2 Aggressive is defined as distant stage at diagnosis or underlying cause of death due to same 
cause as cancer diagnosis. 
3 Significance test for median based on Wilcoxon two-sample test. 
4 Cumulative exposure (in unit-years) is product of the number of days in each department and 
job-title and the assigned score, summed over all jobs worked, and divided by 365.25. 
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SUPPLEMENTAL FILE 
Additional details on state of residence 
Multiple sources of address information were considered. Workers were assumed to have resided 
in the states where the plants were located while employed. Some addresses during the period of 
employment (starting as early as 1939 when the Massachusetts plant opened) were available 
from plant personnel records.  Various tracing efforts from previous studies of this cohort 
[Prince, et al. 2006; Ruder, et al. 2006; Silver, et al. 2009] included the Internal Revenue Service, 
Post Office, and credit services.  Together, these sources provided address information for 
22,249 eligible workers (97%). Finally, eligible workers were also matched to LexisNexis® (a 
private vendor of residential information) in 2011 using first and last name, last known address, 
date of birth and Social Security Number (SSN); this provided additional address information for 
19,235 eligible workers (84%). 
 
Since only changes in the state of residence were relevant, these sources of address information 
were combined to create a residence history for each worker. State of residence was estimated 
for time periods with no known address information by dividing the gap at the midpoint and 
assigning the earlier state to the first half of the gap and the later state to the second half. For a 
given follow-up year, the worker was considered to be in the registry catchment if known to be 
living in at least one state associated with the catchment in that year. 
 
SIR sensitivity analyses for prostate cancer 
The primary analysis used data from the nine cancer registries to identify cases and the 
corresponding states to define the catchment. To evaluate the decision to expand the cancer 
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registries beyond the states where the plants were located, life-table analyses were repeated using 
just the cancer registries for the three study states (and defining the catchment to be New York 
1976-1981; New York and Massachusetts 1982-1986; and New York, Massachusetts, and 
Indiana 1987-2007). 
 
Because state cancer registries generally will not release information about tumors only known 
to them through other state registries, we evaluated the potential under-ascertainment of incident 
cases by repeating life-table analyses additionally including prostate cancer deaths identified 
from our earlier mortality study that occurred in any of the nine cancer registry states [Ruder, et 
al. 2014] that may not have been included as cases in the primary analysis. For these, we 
estimated an approximate diagnosis date as seven years prior to the death date [Antonarakis, et 
al. 2007] and required the estimated diagnosis date to be in the catchment. 
 
The primary analysis was limited to person-time in the first (initial) risk period; however, since 
others have considered disjoint risk periods when estimating SIRs [Bender, et al. 2007] we 
performed additional life-table analyses that considered all person-time while residing in the 
catchment. 
 
In the absence of complete residential histories, Bender et al. [Bender, et al. 2006] recommended 
conducting uncertainty analyses to understand the limitations of the available residential history 
information. Our primary analysis assigned states of residence to gaps in the residential history 
by splitting the gap at the midpoint. To evaluate this decision, we repeated the life-table analyses 
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assigning the entire gap to the earlier state. Next we repeated the life-table analyses assigning the 
entire gap to the later state. 
 
Since the date last observed was updated based on cancer registry information for nine workers 
previously thought to be dead (n=1) or lost to follow-up (n=8) we repeated the life-table analyses 
excluding these workers because other workers lost to follow-up not known to have been 
diagnosed with cancer were not similarly brought forward. 
 
External analyses for prostate cancer 
Plant-specific prostate cancer SIRs were compared using Poisson regression models (SAS 9.2 
GENMOD procedure, SAS Institute Inc., Cary, NC): the dependent variable was the number of 
cases (assumed to follow a Poisson distribution); the independent variables included plant 
indicator variables, and an offset term (with parameter fixed at 1.0) reflected the expected 
number of prostate cancer cases in each age and calendar-year stratum. Model parameters 
reflected the ratios of SIRs and can be interpreted as standardized rate ratios in the absence of a 
plant-age interaction [Armstrong 1995]. Similar methods were used to compare prostate cancer 
SIRs between short-term (<90 days of employment) and long-term workers. 
 
Internal analyses for prostate cancer 
Directly standardized prostate cancer incidence rates among workers with higher cumulative 
exposure were compared to rates among workers in the lowest cumulative exposure category. 
SRR 95% CIs were estimated using approximate methods [Rothman and Greenland 1998] and 
tests of linear trend for cumulative exposure using methods described by Rothman [Rothman 
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1986]. To account for potential latency, we considered exposure lag periods of 0, 10, 20, and 30 
years.  
 
Cox regression was used to estimate prostate cancer hazard ratios for workers with higher 
compared with lower cumulative exposure. In these analyses, age was specified as the time 
variable, cumulative exposure was time-dependent, and controls were matched to cases within 
risk sets on race and attained age. All eligible controls were included and the resulting matched 
risk sets were analyzed using conditional logistic regression (SAS 9.2 PHREG procedure, ibid.), 
equivalent to a Cox proportional hazards model stratified on race. Various transformations of 
cumulative exposure (continuous variable) were evaluated including square root, natural log, and 
restricted cubic splines. Categorical models used quintiles of the exposure distribution among 
cases. Confounding was evaluated for birth and calendar year. Exposure lag periods of 0 to 30 
years were evaluated; the best-fitting lag period was selected based on model fit (AIC, Akaike’s 
Information Criterion). Cutpoints partitioning exposure into three windows by levels of 
hormonal activity--exposure accrued before age 23, from age 23 to age 49, and at 50 years or 
older – were also considered [Agalliu, et al. 2005]. Effect modification was evaluated for plant 
using the likelihood ratio test for interaction. To evaluate the effect of changes in prostate cancer 
screening and guidelines in the late 1980s, we tested for interaction between cumulative 
exposure and calendar year. The proportional hazards assumption was evaluated by the 
likelihood ratio test for interaction between age and cumulative exposure. 
 
We repeated internal analyses (SRRs and Cox regression) after excluding short-term workers 
because a large percentage of the cohort had worked fewer than 90 days [Ruder, et al. 2014]. 
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SUPPLEMENTAL RESULTS 
Cancer diagnoses and ascertainment 
Diagnosis dates of included cancers were based on year only for 28 matches, month and year 
only for 2106 matches, and complete for 1946 matches. The cancer registries were unable to 
provide a diagnosis year for four matches; for these, a diagnosis date was imputed as the date of 
death minus the approximate duration with the disease, when available (n=2), or as the midpoint 
of the years for which the registry was in operation (n=2).  
 
Matching the cohort to the cancer registries led to our extending date last observed for 23 
workers previously thought to be lost to follow-up and two workers previously thought to be 
deceased. After excluding ineligible workers who had died (n=1306) or were otherwise lost to 
follow-up (n=656) before their respective cancer registry was in operation, 22,903 workers were 
eligible for the primary cancer incidence analysis (10,993 male workers were eligible for the 
prostate cancer analysis). Through 2007, 7006 (31%) of the eligible workers died and 6055 
(86%) of these deaths occurred in one of the nine registry states (Indiana, 559; Massachusetts, 
2735; New York, 1867; California, 166; Connecticut, 77; Florida, 463; North Carolina, 57; 
Rhode Island, 77; and Texas, 54); the remaining deaths occurred in other states, U.S territories, 
or the District of Columbia (n=872), or at unknown locations (n=79) (Supplemental Table S1). 
 
Results of internal analyses for prostate cancer 
In separate Cox regression models, both birth year and calendar year were confounders. Results 
were adjusted for calendar year since prostate cancer incidence increased dramatically starting in 
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the late 1980s when prostate-specific antigen screening began [Etzioni, et al. 1999], and 
continuing in 1992 when screening was recommended for asymptomatic men over 50 [American 
Cancer Society 2012]. Results (not shown) were similar when exposure lag periods of 10, 20, 
and 30 years were applied; results are presented based on a 20-year lag period which was best-
fitting in an earlier analysis of prostate cancer mortality [Ruder, et al. 2014]. In simple models, 
prostate cancer incidence was not significantly associated with cumulative exposure 
(Supplemental Table S6, Models 1 and 3). Adjusting for calendar year improved model fit, but 
associations remained null (Supplemental Table S6, Models 2 and 4). Associations remained null 
(data not shown) for models that excluded short-term workers, that evaluated transformations of 
cumulative exposure (log, square root, and restricted cubic spline), and that evaluated exposure 
age windows. Plant and calendar year were evaluated and determined not to be effect modifiers.  
Including terms for time since last exposure did not improve model fit and the adjusted 
association remained null. The assumption of proportional hazards was not violated (data not 
shown). 
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Supplemental Table S1:  Cancer registries, ascertainment, and cohort deaths among 22,903 
PCB cohort members eligible for the cancer incidence study 
 
State 
PCB plant 
located  
here 
Complete  
ascertainment 
 from 
Cohort  
deaths  
through 2007 
California No 1988 166 2.4% 
Connecticut No 1973 77 1.1% 
Indiana Yes 1987 559 8.0% 
Florida No 1997 463 6.6% 
Massachusetts Yes 1982 2735 39.0% 
New York Yes 1976 1867 26.6% 
North Carolina No 1999 57 0.8% 
Rhode Island No 1986 77 1.1% 
Texas No 1995 54 0.8% 
Total in registry states   6055 86.4% 
Other states, territories, or District of Columbia No  872 12.4% 
Unknown No  79 1.1% 
Total   7006 100% 
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Supplemental Table S2: Recode from ICD-O-3 codes reported by cancer incidence registries to diagnostic minor codes used in the 
NIOSH Lifetable Analysis System (LTAS.NET) 
1 
 
Major Category  Minor  Minor Category  ICD-10 Codes  ICD-O-3 Site Codes  ICD-O-3 Histology Codes  
MN of buccal cavity 
and pharynx 
1  MN of lip  C00  C000-C009  All excluding 9140, 9050-9055, and 9590-
9989  2  MN of tongue  C01, C02  C019-C029  
3  MN of other buccal 
cavity  
C03-C08  C039-C069, C079-
C089  
4  MN of pharynx  C09-C14  C090- C119, C129-
C148  
MN of colon and 
rectum  
5  MN of colon  C18  C180-C189 
6  MN of rectum  C19, C20  C199, C209  
MN of other 
digestive organs and 
peritoneum  
7  MN of esophagus  C15  C150- C159  
8  MN of stomach  C16  C160-C169  
9  MN of small 
intestine  
C17  C170-C179  
10  MN of biliary, liver, 
gall bladder  
C22-C24  C220, C221, C239-
C249  
11  MN of pancreas  C25  C250-C259  
12  MN of anus, 
peritoneum, other, 
and unspecified 
digestive  
C21, C26, C48  C210-C212, C218, 
C260, C268, C269, 
C422, C480-C482, 
C488  
MN of respiratory 
and intrathoracic 
organs  
13  MN of larynx  C32  C320-C329  
14  MN of trachea, 
bronchus, and lung  
C33, C34  C339-C349  
15  MN of pleura  C38.4  C384  
16  MN of other 
respiratory and 
intrathoracic organs  
C30, C31, C37, 
C38.0-C38.3, C38.8, 
C39  
C300,C301, C310-
C319, C379, C380-
C383, C388, C390, 
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Major Category  Minor  Minor Category  ICD-10 Codes  ICD-O-3 Site Codes  ICD-O-3 Histology Codes  
C398, C399  
MN of breast  17  MN of breast  C50  C500-C509  
MN of female genital 
organs  
18  MN of cervix uteri  C53  C530-C539  
19  MN of other and 
unspecified parts of 
uterus  
C54, C55, C58  C540-C549, C559, 
C589  
20  MN of ovary, 
fallopian tube, and 
broad ligament  
C56, 57.0-C57.4, 
C57.8  
C569-C574, C578  
21  MN of other and 
unspecified female 
genital organs  
C51, C52, C57.7, 
C57.9  
C510-C519, C529, 
C577, C579  
MN of male genital 
organs  
22  MN of prostate  C61  C619  
23  MN of testes  C62  C620-C629  
24  MN of other and 
unspecified male 
genital organs  
C60, C63  C600-C609, C630-
C639  
MN of urinary 
organs  
25  MN of kidney  C64-C66  C649, C659, C669  
26  MN of bladder and 
other urinary organs  
C67, C68, D09.0
 2
 C670-C689  
MN of thyroid and 
other endocrine 
glands  
27  MN of thyroid gland  C73  C739  
28  MN of other 
endocrine glands  
C74, C75  C740-C749, C750-
C759  
MN of other solid 
cancers  
29  MN of bone  C40, C41  C400-C419  
30  Malignant melanoma 
of skin  
C43  C440-C449  8720-8790  
31  Kaposi sarcoma  C46  Not used  9140  
32  Mesothelioma  C45  Not used  9050-9055  
33  MN of connective C49  C490-C499  All excluding 9140, 9050-9055, and 9590-
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Major Category  Minor  Minor Category  ICD-10 Codes  ICD-O-3 Site Codes  ICD-O-3 Histology Codes  
tissue  9989  
34  MN brain and other 
parts of nervous 
system  
C47, C70-C72  C470-C479, C700-
C729  
35  MN eye  C69  C690-C699  
Malignant neoplasms 
of lymphatic and 
hematopoietic tissue  
36  Hodgkin lymphoma  C81  Not used  9650- 9667  
37  Non-Hodgkin 
lymphoma  
C82-C85, C88.0, 
C88.3, C91.4, 
C96.0-C96.3, C96.7  
Not used  9590, 9591, 9596, 9670, 9671, 9673, 9675, 
9678- 9680, 9684, 9687, 9688, 9689-9691, 
9695, 9698-9702, 9705, 9708, 9709, 9712, 
9714-9719, 9724-9729, 9735, 9737, 9738, 
9740, 9750, 9754-9759, 9761, 9764, 9940  
38  Multiple myeloma  C90  Not used  9731-9734  
39  Leukemia and 
aleukemia  
C91.0-C91.3, C91.5, 
C91.7, C91.9, C92-
C95  
Not used  9742, 9800, 9801, 9805, 9820, 9823, 9826, 
9827, 9831-9837, 9840, 9860, 9861, 9863, 
9866, 9867, 9870-9876, 9891, 9895-9897, 
9910, 9920, 9930, 9931, 9945, 9946, 9948, 
9963  
40  Other lymphatic and 
hematopoietic 
neoplasms  
C88.2, C88.7, 
C88.9, C96.9, D45, 
D46.1-D46.4, 
D46.7, D46.9, 
D47.1, D47.3, 
D47.7  
Not used  9751, 9760, 9762, 9950, 9960-9962, 9970, 
9975, 9980, 9982-9987, 9989  
Ill-specified and 
residual  
41  MN of Ill-specified 
and residual sites  
C44, C76, C77, 
C80, C97  
C440-C449  All excluding 8720-8790, 9140, 9050-9055, 
and 9590-9989  
C760-C768, C809, 
C420-C424, C770-
C779  
All excluding 9140, 9050-9055, and 9590-
9989  
Abbreviations: ICD-O-3, International Classification of Diseases for Oncology, 3rd Edition; ICD-10, International Classification of Diseases, 
10th Revision; MN, malignancy; SEER, Surveillance, Epidemiology, and End Results Program 
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1
 Table adapted from supplemental table S5 in Daniels RD, Kubale TL, Yiin JH, Dahm MM, Hales TR, Baris D, Zahm SH, Beaumont JJ, 
Waters KM, Pinkerton LE. Mortality and cancer incidence in a pooled cohort of U.S. firefighters from San Francisco, Chicago and 
Philadelphia. Occupational and Environmental Medicine 2014;71:388-97. 
2
 Urinary bladder incidence cases originally coded in situ (Behavior=2) were recoded to invasive (Behavior=3) per SEER protocol. 
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Supplemental Table S3: Prostate cancer standardized incidence ratios 
 
Analysis 
1
 
No. 
workers 
2
 PYAR OBS EXP SIR 95% CI 
All workers 9905 193,960.3 454 515.6 0.88 0.80-0.97 
By plant       
Indiana 2208 37,631.0 99 123.1 0.80 0.65-0.98 
Massachusetts  3319 64,341.4 167 180.6 0.92 0.79-1.08 
New York  4378 91,987.8 188 211.9 0.89 0.77-1.02 
By employment duration       
Short-term workers (< 90 days) 2638 51,462.5 96 108.9 0.88 0.71-1.08 
Long-term workers (90+ days) 7267 142,497.8 358 406.7 0.88 0.79-0.98 
 
Abbreviations: PYAR – person-years at risk, OBS – observed number of cases, EXP – expected number 
of cases based on SEER rates, SIR – standardized incidence ratio, CI – confidence interval 
 
1
 The analysis included prostate cancer cases identified using the nine state cancer registries (CT, NY, 
MA, RI, IN, CA, TX, FL, and NC); split any gaps in the residence history at the midpoint and 
assigned the first half of the gap to the earlier state and the second half of the gap to the later state; 
and limited person-time at risk to the initial risk period (i.e., person-time at risk was censored at the 
date the worker was first known to be living outside the catchment). 
2
 The number of workers (9905) and prostate cancer cases (454) differs slightly from those reported in 
table 2 (9891 and 432, respectively) because the prostate cancer analysis only excluded workers with 
a prostate cancer diagnosis before the cancer registry begin date whereas the analysis of first primary 
cancer excluded workers with any cancer diagnosis before the cancer registry begin date. 
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Supplemental Table S4: Prostate cancer standardized incidence ratios for the sensitivity analyses 
Sensitivity analyses 
No. 
workers PYAR OBS EXP SIR 95% CI 
S1: Included only cases from the IN, MA, and NY 
cancer registries 
1
 
9134 181,478.6 396 464.3 0.85 0.77-0.94 
S2: Included (a) all cancer-registry identified cases 
(primary) and (b) death-certificate identified cases 
who resided in any of the nine registry states 
2
 
9899 193,902.5 465 515.1 0.90 0.82-0.99 
S3: Included all risk periods 
3
 9898 200,632.2 473 541.7 0.87 0.80-0.96 
S4: Assigned entire gap to earlier state 
4
 10549 215,287.0 454 531.2 0.85 0.78-0.94 
S5: Assigned entire gap to later state 
5
 9492 194,584.6 470 535.5 0.88 0.80-0.96 
S6: Excluded “lost and found” workers 
6
 9896 193,821.6 451 515.1 0.88 0.80-0.96 
 
Abbreviations: PYAR – person-years at risk, OBS – observed number of cases, EXP – expected number 
of cases based on SEER rates, SIR – standardized incidence ratio, CI – confidence interval 
The primary analysis included cases identified using the nine state cancer registries (CT, NY, MA, RI, 
IN, CA, TX, FL, and NC); split any gaps in the residence history at the midpoint and assigned the first 
half of the gap to the earlier state and the second half of the gap to the later state; and limited person-
time at risk to the initial risk period (i.e., person-time at risk was censored at the date the worker was 
first known to be living outside the catchment). 
1
 S1 was like the primary analysis except that it defined the catchment to be the states where the plants 
were located (NY, MA, and IN) and limited cases to those identified using the cancer registries 
affiliated with these three states. 
2
 S2 was like the primary analysis except that it additionally included cases from the nine registry 
states who were identified using death certificates. 
3
 S3 was like the primary analysis except that all risk periods were included (i.e., all person-time at 
risk in the catchment contributed to the denominator). 
4
 S4 was like the primary analysis except that gaps in the residence history were assigned to the earlier 
state. 
5
 S5 was like the primary analysis except that gaps in the residence history were assigned to the later 
state. 
6
 S6 was like the primary analysis except that nine “lost and found” workers were excluded.\ 
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Supplemental Table S5: Observed and expected numbers of incident prostate cancers, 
standardized incidence ratios, and directly standardized rate ratios, by exposure category 1 
Cumulative exposure category (unit-years) 
2
 PYAR OBS EXP SIR 95% CI  SRR 95% CI 
Unlagged         
1: <23 42,320.7 90 102.5 0.88 0.71-1.08  1 (referent) 
2: 23-<99 42,019.1 90 100.1 0.90 0.72-1.11  1.06 0.78-1.42 
3: 99-<330 42,457.4 90 104.9 0.86 0.69-1.05  1.03 0.76-1.38 
4: 330-<1100 35,085.5 89 90.7 0.98 0.79-1.21  1.16 0.86-1.56 
5: 1100+ 30,220.4 88 108.8 0.81 0.65-0.997  1.00 0.73-1.38 
        ptrend=0.99 
20 year lag         
1: <23 74,696.8 90 107.9 0.83 0.67-1.02  1 (referent) 
2: 23-<86 30,924.1 91 89.9 1.01 0.82-1.24  1.25 0.93-1.68 
3: 86-<320 36,098.5 90 111.6 0.81 0.65-0.99  1.02 0.76-1.37 
4: 320-<1100 27,792.0 89 92.0 0.97 0.78-1.19  1.18 0.88-1.58 
5: 1100+ 22,591.9 87 105.6 0.82 0.66-1.02  1.07 0.78-1.47 
        ptrend=0.90 
 
Abbreviations: PYAR – person-years at risk, OBS – observed number of cases, EXP – expected number 
of cases based on SEER rates, SIR – standardized incidence ratio, CI – confidence interval, SRR – 
standardized rate ratio, ptrend – p-value for linear trend test 
 
1
 Results exclude seven cases and 1857 PYAR with unknown cumulative exposure. 
2
 Categories of cumulative exposure based on the quintiles of the lag-specific case distribution. 
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Supplemental Table S6: Cox regression models for prostate cancer incidence with estimated 
cumulative exposure (lagged by 20 years) 
1
 
 
Model term 
Model 1  Model 2  Model 3  Model 4 
HR 95% CI HR 95% CI HR 95% CI HR 95% CI 
Cumulative exposure            
At 1000 unit-years 0.965 0.913-1.013  0.980 0.929-1.028       
Category (unit-years)            
1: <23       1 (reference)  1 (reference) 
2: 23-<86        1.23 0.92-1.65  1.20 0.90-1.62 
3: 86-<320       1.00 0.74-1.33  1.00 0.74-1.34 
4: 320-<1100        1.16 0.86-1.56  1.14 0.85-1.54 
5: 1100+        0.95 0.70-1.27  1.04 0.77-1.40 
Calendar year            
<1990    1 (reference)     1 (reference) 
1990-1994    2.73 1.79-4.26     2.71 1.77-4.23 
1995-1999    3.42 2.32-5.21     3.41 2.31-5.20 
2000+    3.42 2.38-5.12     3.43 2.38-5.12 
            
Likelihood ratio test for exposure            
Degrees of freedom 1  1  4  4 
Chi-square 1.98  0.62  4.40  2.56 
P-value 0.16  0.43  0.35  0.63 
            
Model fit            
-2 log likelihood 7036.58  6977.98  7034.16  6796.04 
Akaike’s information criterion 7038.58  6985.98  7042.16  6990.04 
            
 
Abbreviations: HR – hazard ratio, CI – profile likelihood based confidence interval 
 
1 For all models, controls were matched to cases within risk sets on race in addition to attained age 
and all eligible controls were included. Cumulative exposure (lagged by 20 years) was evaluated 
within risk sets at the case’s failure age and treated as a continuous variable in models 1 and 2 and as 
a categorical variable in models 3 and 4. The effect of cumulative exposure is adjusted for age at 
diagnosis in models 1 and 3 and for age at diagnosis and calendar year in models 2 and 4.  
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